A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity

Oncology
Yoon Hee ChoiYoon-Koo Kang

Abstract

We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer. We also evaluated the association between UGT1A1 and CYP2A6 polymorphisms and clinical phenotypes. The patients received CPT-11 (225 mg/m(2)) on day 1 and S-1 (80 mg/m(2)) on days 1-14 every 3 weeks. The association of the UGT1A1 (*6 and *28) and CYP2A6(*4, *7, *9, and *10) polymorphisms with toxicities and efficacy were analyzed. Thirty patients were treated. The overall response rate was 66.7% (95% CI 48.7-84.6). The median time to progression was 7.6 months (95% CI 5.8-9.5). The most common grade 3/4 hematologic and non-hematologic toxicity were neutropenia (53.4%) and diarrhea (16.7%), respectively. The allele frequencies of UGT1A1*6 and *28 were 15.5 and 10.3%, respectively. The frequencies of CYP2A6*4, *7, *9, and *10 were 15.5, 8.6, 29.3, and 3.5%, respectively. Stratification of patients according to the number of UGT1A1*28 and *6 alleles showed a significant correlation between the number of defective alleles and the incidence of grade 3/4 neutropenia. Our results indicate that IRIS is a promising first-line regimen in patients with metastatic ...Continue Reading

References

Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Mar 10, 2001·Biochemical and Biophysical Research Communications·N AriyoshiT Kamataki
May 7, 2002·The Pharmacogenomics Journal·L IyerM J Ratain
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M L VeroneseP J O'Dwyer
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
May 3, 2005·Pharmacogenetics and Genomics·Federico InnocentiMark J Ratain
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Dell'Italia Meridionale
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GotoK Shirao
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ji-Youn HanJin Soo Lee
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Jan 29, 2008·Therapeutic Drug Monitoring·Sung Su YeaJae-Gook Shin
Jul 3, 2008·British Journal of Cancer·D M KweekelUNKNOWN Dutch Colorectal Cancer Group study
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Erika CecchinGiuseppe Toffoli
Jul 14, 2010·Cancer Chemotherapy and Pharmacology·Manabu ShiozawaSoichiro Morinaga

❮ Previous
Next ❯

Citations

Dec 7, 2013·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Yi-Jing ChenQing Xu
Jan 12, 2016·Therapeutic Advances in Medical Oncology·William A HammondKabir Mody

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.